E1

Roche’s Nearly $2B Atavistik Bet Goes After Cardiometabolic Targets Other Drugs Struggle to Reach

The Future of Cardiology Starts Before the First Heart Attack

Novo’s €1.165B Bet Targets the Burden of Weekly Injections

Novo’s $1.4B Orbis Deal Bets on a New Route to Oral Cardiometabolic Drugs

Britain Wants an AI-Enabled NHS. Scaling Innovation Is Still the Bottleneck

Medical AI can ace the benchmark and still fail the clinic. Real-world evidence is the next test

AI can find hidden heart disease in routine ECGs. The policy challenge is deciding who gets fast-tracked

The Novo Nordisk Foundation is going global on cardiometabolic disease.

Military recruits appear to face far more sudden cardiac death than athletes. Screening still depends on the country
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
